Unknown OBSERVATIONAL NCT03882684

Role of Genomic Imprinting in Cancer Diagnosis

Sponsor: Chinese Alliance Against Lung Cancer

Conditions Biomarker Cancer Early Diagnosis Genomic Imprinting

Interventions In-situ imprinting detection

Updated 7 times since 2019 Last updated: Mar 18, 2019 Started: Jul 1, 2017 Primary completion: Mar 31, 2019 Completion: Jun 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Biomarker and Cancer and is currently ongoing. Chinese Alliance Against Lung Cancer leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Dec 2021 — Jul 2024 [monthly]

Unknown Status
Oct 2021 — Dec 2021 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting

▶ Show 2 earlier versions

Nov 2020 — Jan 2021 [monthly]

Recruiting
Apr 2019 — Nov 2020 [monthly]

Recruiting

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Alliance Against Lung Cancer
LiSen Imprinting Diagnostic Inc.

Data source: Chinese Alliance Against Lung Cancer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China